|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
|
ES2118941T3
(es)
*
|
1992-02-21 |
1998-10-01 |
Alcon Lab Inc |
Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.
|
|
EP0660703A1
(en)
*
|
1992-09-17 |
1995-07-05 |
Alcon Laboratories, Inc. |
Topical carbonic anhydrase inhibitor composition
|
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
|
AU684950B2
(en)
*
|
1994-05-06 |
1998-01-08 |
Alcon Laboratories, Inc. |
Use of vitamin E tocopheryl derivatives in ophthalmic compositions
|
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
CA2237898A1
(en)
*
|
1995-11-17 |
1997-05-29 |
Louis Desantis Jr. |
Combination therapy for treating glaucoma
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
|
CH690814A5
(it)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Composizioni per uso topico contenenti polisaccaridi solfati.
|
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
|
AU2183900A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
|
WO2000038690A2
(en)
|
1998-12-24 |
2000-07-06 |
Alcon Laboratories, Inc. |
Prostaglandin e agonists for treatment of dry eye
|
|
ATE312103T1
(de)
*
|
1999-01-25 |
2005-12-15 |
Nat Jewish Med & Res Center |
Substituierte porphyrine und deren therapeutische verwendungen
|
|
DE60003445T2
(de)
|
1999-11-01 |
2003-12-24 |
Alcon, Inc. |
Pharmazeutische zusammensetzungen ein fluorchinolonantibiotikum und xanthangummi enthaltend
|
|
DK1228027T3
(da)
|
1999-11-09 |
2004-07-19 |
Alcon Inc |
3-heteroatomsubstituerede og to carbonhomologe af 15-HETE og fremgangsmåder til anvendelse
|
|
ATE258791T1
(de)
|
1999-11-09 |
2004-02-15 |
Alcon Inc |
Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
|
|
US6353032B1
(en)
|
1999-11-09 |
2002-03-05 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
MXPA02004700A
(es)
|
1999-11-09 |
2004-09-10 |
Alcon Inc |
Compuestos relacionados con acido 15-hidroxieicosatetraenoico y metodos de uso.
|
|
WO2001034550A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
|
PT1228030E
(pt)
|
1999-11-09 |
2005-08-31 |
Alcon Inc |
Derivados benzenoidicos do acido 15-hidroxieicosatetraenoico e metodos para a sua utilizacao no tratamento das perturbacoes do olho seco
|
|
BR0015436A
(pt)
|
1999-11-09 |
2002-07-16 |
Alcon Inc |
Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos
|
|
ES2220561T3
(es)
|
1999-11-09 |
2004-12-16 |
Alcon Inc. |
Composiciones que contienen derivados de acido hidroxieicosa tetraenoico y metodo de uso para tratar trastornos de la xeroftalmia.
|
|
EP1227809B1
(en)
|
1999-11-09 |
2005-04-06 |
Alcon Inc. |
Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
|
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
ES2208440T3
(es)
|
1999-11-09 |
2004-06-16 |
Alcon Inc. |
Derivados del acido 15-hidroxieicosatetraenoico con cadena omega modificada utiles para el tratamiento del ojo seco.
|
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
WO2001034553A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
|
WO2001046134A1
(en)
|
1999-12-22 |
2001-06-28 |
Alcon Universal Ltd. |
6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
|
|
AU2001270593A1
(en)
|
2000-07-28 |
2002-02-13 |
Alcon Universal Ltd. |
Pharmaceutical compositions containing tobramycin and xanthan gum
|
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
|
US7060297B2
(en)
|
2000-11-06 |
2006-06-13 |
Alcon, Inc. |
Carrageenan viscoelastics for ocular surgery
|
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
|
BR0209882A
(pt)
*
|
2001-05-21 |
2004-06-08 |
Alcon Inc |
Método para o tratamento de distúrbios de olho seco
|
|
ES2278049T3
(es)
|
2001-05-21 |
2007-08-01 |
Alcon, Inc. |
Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
|
|
DK1393277T3
(da)
|
2001-05-21 |
2006-10-30 |
Alcon Inc |
Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser
|
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
|
EP1439842A4
(en)
*
|
2001-06-01 |
2009-09-02 |
Nat Jewish Med & Res Center |
OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
|
|
US6750250B1
(en)
*
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
|
EP1448218A4
(en)
*
|
2001-10-23 |
2009-01-14 |
Oklahoma Med Res Found |
BETA SECRETASE INHIBITORS AND METHOD OF USE
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
EP1478404A1
(en)
*
|
2002-02-22 |
2004-11-24 |
Pharmacia Corporation |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
|
|
JP2005521690A
(ja)
*
|
2002-02-22 |
2005-07-21 |
ファルマシア・コーポレーション |
ゴム系を含む眼科用製剤
|
|
EP2316459B1
(en)
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
|
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
|
WO2004060274A2
(en)
*
|
2002-12-20 |
2004-07-22 |
Alcon, Inc. |
Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
|
|
DK1663242T3
(da)
|
2003-08-07 |
2011-08-01 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
|
|
JP5222462B2
(ja)
*
|
2003-08-21 |
2013-06-26 |
スキャンポ・アーゲー |
眼科用組成物
|
|
US7659289B2
(en)
*
|
2004-09-17 |
2010-02-09 |
Comentis, Inc. |
Hydroxyethylene-based β-secretase inhibitors and use thereof
|
|
JP2008513495A
(ja)
*
|
2004-09-17 |
2008-05-01 |
コメンティス，インコーポレーテッド |
ベータ−セクレターゼ活性を阻害する二環式化合物およびその使用方法
|
|
US9512125B2
(en)
*
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
|
MX2007012341A
(es)
*
|
2005-04-08 |
2008-02-12 |
Comentis Inc |
Compuestos que inhiben actividad beta-secretasa y metodos de uso de los mismos.
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
|
ES2431466T3
(es)
|
2006-06-30 |
2013-11-26 |
Sunesis Pharmaceuticals, Inc. |
Inhibidores de piridinonil pdk1
|
|
WO2008064274A1
(en)
|
2006-11-21 |
2008-05-29 |
Rigel Pharmaceuticals, Inc. |
Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
|
|
KR20080076667A
(ko)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
요변성 약학 조성물
|
|
EP2170283B1
(en)
|
2007-06-22 |
2019-01-09 |
Board of Regents, The University of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
|
EP2178837A2
(en)
*
|
2007-07-26 |
2010-04-28 |
Comentis, Inc. |
Isophthalamide derivatives inhibiting beta-secretase activity
|
|
CN101868457B
(zh)
*
|
2007-09-24 |
2013-02-13 |
科门蒂斯公司 |
作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
|
|
EP2234608A2
(en)
|
2007-12-11 |
2010-10-06 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
|
MX2010009857A
(es)
*
|
2008-03-07 |
2010-12-07 |
Sun Pharma Advanced Res Co Ltd |
Composicion oftalmica.
|
|
DK2300003T3
(da)
|
2008-05-23 |
2014-05-26 |
Nat Jewish Health |
Forbindelser til anvendelse i behandling af skade forbundet med eksponering for en alkylerende art
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
|
CN104230901A
(zh)
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
|
EP2382210B1
(en)
|
2008-12-30 |
2017-03-01 |
Rigel Pharmaceuticals, Inc. |
Pyrimidinediamine kinase inhibitors
|
|
PL2389372T3
(pl)
|
2009-01-23 |
2016-02-29 |
Rigel Pharmaceuticals Inc |
Kompozycje i sposoby hamowania szlaku JAK
|
|
EP3620154A1
(en)
|
2009-02-06 |
2020-03-11 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
|
RU2482851C2
(ru)
*
|
2009-02-20 |
2013-05-27 |
Микро Лабс Лимитед |
Хранение стабильного продукта простагландина
|
|
MX337849B
(es)
|
2009-07-28 |
2016-03-09 |
Rigel Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de la via jak.
|
|
NZ623069A
(en)
|
2009-08-17 |
2015-11-27 |
Sloan Kettering Inst Cancer |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
|
WO2011029043A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Heteroaryl btk inhibitors
|
|
TWI557127B
(zh)
|
2009-09-04 |
2016-11-11 |
百健Ｍａ公司 |
布魯頓氏酪胺酸激酶抑制劑
|
|
PL2485731T4
(pl)
|
2009-10-06 |
2017-07-31 |
Millennium Pharmaceuticals, Inc. |
Związki heterocykliczne użyteczne jako inhibitory PDK1
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
DK2853262T3
(da)
|
2009-10-26 |
2017-03-06 |
Sephoris Pharmaceuticals Llc |
Behandling af solskoldning ved anvendelse af analgetika og antihistaminer
|
|
CN102711765A
(zh)
|
2009-11-16 |
2012-10-03 |
加利福尼亚大学董事会 |
激酶抑制剂
|
|
ES2546063T3
(es)
|
2009-12-10 |
2015-09-18 |
The Regents Of The University Of California |
Agentes de enlace a amiloides
|
|
CN104744215B
(zh)
|
2010-03-03 |
2019-03-15 |
尼昂克技术公司 |
包含单萜的药物组合物
|
|
SG10201502484SA
(en)
|
2010-03-30 |
2015-05-28 |
Verseon Corp |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
|
SI2563771T1
(sl)
|
2010-04-24 |
2016-05-31 |
Viamet Pharmaceuticals, Inc. |
Spojine inhibitorjev metaloencimov
|
|
KR101937495B1
(ko)
|
2010-07-28 |
2019-01-10 |
리겔 파마슈티칼스, 인크. |
Ｊａｋ 경로의 억제를 위한 조성물 및 방법
|
|
US9499461B2
(en)
|
2010-08-27 |
2016-11-22 |
Neonc Technologies, Inc. |
Pharmaceutical compositions comprising POH derivatives
|
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
CA2816088A1
(en)
|
2010-10-28 |
2012-05-03 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
US9273028B2
(en)
|
2010-10-29 |
2016-03-01 |
Biogen Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
|
EP2638021B1
(en)
|
2010-11-13 |
2018-09-26 |
Innocrin Pharmaceuticals, Inc. |
1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer
|
|
AU2011343966B2
(en)
|
2010-12-13 |
2017-03-16 |
Innocrin Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
ES3056006T3
(en)
|
2010-12-17 |
2026-02-17 |
Univ Southern California |
Methods and devices for using isoperillyl alcohol
|
|
JP5885271B2
(ja)
|
2011-02-14 |
2016-03-15 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
ビマトプロストのエステル誘導体の組成物および方法
|
|
CN103649028B
(zh)
|
2011-02-25 |
2015-10-14 |
美国政府健康及人类服务部 |
抑制FtsZ蛋白的克利斯汀类似物
|
|
WO2012149416A2
(en)
|
2011-04-28 |
2012-11-01 |
University Of Southern California |
Human myeloid derived suppressor cell cancer markers
|
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
DK2710007T3
(da)
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
Kinasehæmmere
|
|
AU2012255860C1
(en)
|
2011-05-17 |
2015-12-10 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
WO2012162547A2
(en)
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Long duration dual hormone conjugates
|
|
KR20140040235A
(ko)
|
2011-06-19 |
2014-04-02 |
비아멧 파마슈티컬즈, 인코포레이티드 |
금속효소 억제제 화합물
|
|
WO2012177635A1
(en)
|
2011-06-19 |
2012-12-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
JP2014523880A
(ja)
|
2011-06-23 |
2014-09-18 |
ヴィアメット ファーマスーティカルズ，インコーポレイテッド |
金属酵素化合物
|
|
EP2726097A4
(en)
|
2011-07-01 |
2015-03-11 |
Univ California |
HERPES VIRUS VACCINE AND METHOD OF USE
|
|
WO2013077921A2
(en)
|
2011-09-02 |
2013-05-30 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
US9073851B2
(en)
|
2011-10-28 |
2015-07-07 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer
|
|
RS57248B1
(sr)
|
2011-12-11 |
2018-07-31 |
Viamet Pharmaceuticals Nc Inc |
Jedinjenja inhibitori metaloenzima
|
|
IN2014DN06792A
(da)
|
2012-01-20 |
2015-05-22 |
Viamet Pharmaceuticals Inc |
|
|
WO2013142038A2
(en)
|
2012-03-23 |
2013-09-26 |
Oxigene, Inc. |
Compositions and methods for inhibition of cathepsins
|
|
WO2013155223A1
(en)
|
2012-04-10 |
2013-10-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
EP2858500A4
(en)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
BRUTON TYROSINE KINASE HEMMER
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
JP6270848B2
(ja)
|
2012-08-27 |
2018-01-31 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
SMT201900344T1
(it)
|
2012-09-10 |
2019-07-11 |
Principia Biopharma Inc |
Composti di pirazolopirimidina come inibitori di chinasi
|
|
CA2886240A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
|
WO2014066435A1
(en)
|
2012-10-22 |
2014-05-01 |
City Of Hope |
Etp derivatives
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
AU2014214561C1
(en)
|
2013-02-11 |
2019-01-17 |
Mitokinin, Inc. |
Compositions and methods for treating neurodegenerative diseases
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
|
AU2014236370C1
(en)
|
2013-03-14 |
2019-01-17 |
City Of Hope |
5-bromo-indirubins
|
|
EP2968270A4
(en)
|
2013-03-14 |
2016-08-17 |
Univ California |
MODULATION OF K2P CHANNELS
|
|
AU2014236356A1
(en)
|
2013-03-14 |
2015-09-24 |
The Regents Of The University Of California |
Thiosaccharide mucolytic agents
|
|
WO2014144952A2
(en)
|
2013-03-15 |
2014-09-18 |
Peter Walter |
Modulators of the eif2alpha pathway
|
|
KR20150129735A
(ko)
|
2013-03-15 |
2015-11-20 |
알러간, 인코포레이티드 |
렙틴 생성의 향상을 위한 비마토프로스트
|
|
WO2014149139A2
(en)
|
2013-03-15 |
2014-09-25 |
Verseon, Inc. |
Halogenopyrazoles as inhibitors of thrombin
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
|
KR20150130355A
(ko)
|
2013-03-15 |
2015-11-23 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
비환식 뉴클레오사이드 포스포네이트 디에스테르
|
|
DK2968297T3
(da)
|
2013-03-15 |
2019-01-07 |
Verseon Inc |
Multisubstituerede aromatiske forbindelser som serinproteasehæmmere
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CA2949048A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
|
WO2015009742A2
(en)
|
2013-07-15 |
2015-01-22 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
|
DK3035926T3
(da)
|
2013-08-19 |
2020-08-31 |
Univ California |
Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
|
|
JP2016530273A
(ja)
|
2013-08-20 |
2016-09-29 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
癌を治療するためのｈｄａｃ８阻害剤
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
HRP20181109T1
(hr)
|
2013-12-11 |
2018-11-02 |
Biogen Ma Inc. |
Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
|
|
WO2015089327A1
(en)
|
2013-12-11 |
2015-06-18 |
Biogen Idec Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
MX2016008418A
(es)
|
2013-12-23 |
2017-01-11 |
Memorial Sloan Kettering Cancer Center |
Metodos y reactivos para el radiomarcaje.
|
|
PT2898888T
(pt)
|
2014-01-22 |
2019-07-16 |
Visufarma B V |
Composição que compreende iota-carragenina contra conjuntivite viral
|
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
|
ES2919024T3
(es)
|
2014-02-11 |
2022-07-21 |
Mitokinin Inc |
Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
|
|
CA2937752C
(en)
|
2014-02-14 |
2023-02-07 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
WO2015175075A1
(en)
|
2014-02-20 |
2015-11-19 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
WO2015148839A1
(en)
|
2014-03-26 |
2015-10-01 |
City Of Hope |
Treatment of brca1-defective cancer or resistant cancers
|
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
|
EA201692155A1
(ru)
|
2014-05-13 |
2017-04-28 |
Мемориал Слоун-Кеттеринг Кэнсэ Сентр |
МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
|
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
|
WO2016018917A2
(en)
|
2014-07-28 |
2016-02-04 |
The Regents Of The University Of Califoria |
Compositions and methods of making polymerized nucleic acids
|
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
|
EP3193902A4
(en)
|
2014-09-11 |
2018-03-28 |
The Regents of The University of California |
mTORC1 INHIBITORS
|
|
MX377983B
(es)
|
2014-09-15 |
2025-03-04 |
Univ California |
Análogos de nucleótidos.
|
|
JP2017528486A
(ja)
|
2014-09-17 |
2017-09-28 |
ヴァーセオン コーポレイション |
セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
ES2757798T3
(es)
|
2014-10-02 |
2020-04-30 |
Allergan Inc |
Profármacos de éster de gamma-lactamas y su uso
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
|
AU2016206475B2
(en)
|
2015-01-16 |
2021-11-04 |
City Of Hope |
Cell penetrating antibodies
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
WO2016130800A2
(en)
|
2015-02-12 |
2016-08-18 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising perillyl alcohol derivatives
|
|
DK3261640T3
(da)
|
2015-02-25 |
2022-07-11 |
Univ California |
5ht-agonister til behandling af epilepsilidelser
|
|
KR20170122788A
(ko)
|
2015-02-27 |
2017-11-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
연골 재생을 가능하게 하는 소분자
|
|
ES2931460T3
(es)
|
2015-02-27 |
2022-12-29 |
Verseon Int Corporation |
Compuestos de pirazol sustituido como inhibidores de serina proteasa
|
|
EA039121B1
(ru)
|
2015-02-27 |
2021-12-07 |
Куртана Фармасьютикалс, Инк. |
ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
|
|
CA2981504C
(en)
|
2015-03-30 |
2023-10-24 |
City Of Hope |
Mechanically interlocking complexes
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
CA2982890C
(en)
|
2015-04-17 |
2023-08-22 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
|
CA2983293C
(en)
|
2015-04-24 |
2023-06-20 |
The Regents Of The University Of California |
Modulators of ror1-ror2 binding
|
|
CN107849102B
(zh)
|
2015-05-15 |
2022-05-13 |
希望之城 |
嵌合抗原受体组合物
|
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
|
MA42510A
(fr)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
|
|
US10765696B2
(en)
|
2015-06-10 |
2020-09-08 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
WO2017004357A1
(en)
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
HK1256242A1
(zh)
|
2015-08-04 |
2019-09-20 |
Rigel Pharmaceuticals, Inc. |
吲哚化合物以及制备和使用该化合物的方法
|
|
EP3331543A4
(en)
|
2015-08-06 |
2019-03-20 |
City of Hope |
Cell-pollenizing protein antibody conjugates and methods of use
|
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
|
WO2017040982A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of California |
Her3 ligands and uses thereof
|
|
EP3350167A4
(en)
|
2015-09-04 |
2019-04-03 |
City of Hope |
Androgen receptor Antagonist
|
|
KR102768838B1
(ko)
|
2015-09-17 |
2025-02-14 |
시티 오브 호프 |
Pcna 억제제
|
|
JP7163180B2
(ja)
|
2015-09-25 |
2022-10-31 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ・リミテツド |
３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
CA3001723A1
(en)
|
2015-10-15 |
2017-04-20 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Ｒａｓの阻害剤をスクリーニングするための方法
|
|
US11046670B2
(en)
|
2015-10-19 |
2021-06-29 |
Board Of Regents, The University Of Texas System |
Piperazinyl norbenzomorphan compounds and methods for using the same
|
|
CN108697699A
(zh)
|
2015-10-23 |
2018-10-23 |
苏尼西斯制药有限公司 |
用于治疗癌症的杂环pdk1抑制剂
|
|
CN119241632A
(zh)
|
2015-10-23 |
2025-01-03 |
Erx制药股份有限公司 |
雷公藤红素的类似物
|
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
CN108603037B
(zh)
|
2015-12-10 |
2020-11-17 |
希望之城 |
细胞穿透花青偶联抗体
|
|
RU2730855C2
(ru)
|
2015-12-24 |
2020-08-26 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа |
Кфтр регуляторы и способы их применения
|
|
ES2909316T3
(es)
|
2015-12-24 |
2022-05-06 |
Univ California |
Reguladores de CFTR y métodos de uso de los mismos
|
|
MX376201B
(es)
|
2015-12-30 |
2025-03-07 |
Nqp 1598 Ltd |
Compuestos inhibidores de metaloenzima.
|
|
CA3010445A1
(en)
|
2016-01-05 |
2017-07-13 |
The Regents Of The University Of California |
Benzothiazole amphiphiles
|
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
|
WO2017161344A1
(en)
|
2016-03-17 |
2017-09-21 |
The Regants Of The University Of California |
Compositions and methods for treating parasitic diseases
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
PT3458448T
(pt)
|
2016-04-25 |
2021-09-10 |
Forma Therapeutics Inc |
Inibidores fasn para uso no tratamento de esteato-hepatite não-alcoólica
|
|
CA3022432A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TWI920577B
(zh)
|
2016-05-05 |
2026-04-01 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
PE20190119A1
(es)
|
2016-05-12 |
2019-01-17 |
Anacor Pharmaceuticals Inc |
Esteres de oxaborol y sus usos
|
|
CA3063834C
(en)
|
2016-05-26 |
2025-05-06 |
The Regents Of The University Of California |
ESTROGEN RECEPTOR MODULATOR ASSOCIATIONS
|
|
ES2940911T3
(es)
|
2016-06-27 |
2023-05-12 |
Rigel Pharmaceuticals Inc |
Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
|
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
|
|
WO2018013609A2
(en)
|
2016-07-11 |
2018-01-18 |
The Regents The University Of California |
Synthetic melanin nanoparticles uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CA3031443A1
(en)
|
2016-07-21 |
2018-01-25 |
Biogen Ma Inc. |
Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
|
|
ES2925564T3
(es)
|
2016-07-29 |
2022-10-18 |
Rapt Therapeutics Inc |
Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
|
AU2017327384B2
(en)
|
2016-09-13 |
2021-05-20 |
The Jackson Laboratory |
Targeted enhanced DNA demethylation
|
|
CN109952104B
(zh)
|
2016-09-15 |
2023-03-28 |
希望之城 |
二硫etp衍生物
|
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
CN110099899B
(zh)
|
2016-10-26 |
2024-01-02 |
里格尔药品股份有限公司 |
用作irak抑制剂的噁唑衍生物及其制备方法
|
|
CN110234637B
(zh)
|
2016-10-26 |
2022-11-01 |
里格尔药品股份有限公司 |
用作irak抑制剂的吡唑酰胺化合物
|
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
|
CN110267538B
(zh)
|
2016-11-30 |
2022-04-19 |
尼昂克技术公司 |
紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
|
|
CN110291084A
(zh)
|
2016-12-15 |
2019-09-27 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
WO2018125799A2
(en)
|
2016-12-29 |
2018-07-05 |
Viamet Pharmaceuticals (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
|
CA3055292A1
(en)
|
2016-12-29 |
2018-07-05 |
Selenity Therapeutics (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
WO2018237145A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
JP7167069B2
(ja)
|
2017-06-29 |
2022-11-08 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
キナーゼ阻害剤ならびに作製および使用のための方法
|
|
US11554178B2
(en)
|
2017-06-30 |
2023-01-17 |
City Of Hope |
Compositions and methods of modulating macrophage activity
|
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
JP2020536072A
(ja)
|
2017-09-29 |
2020-12-10 |
ジェネンテック， インコーポレイテッド |
ペプチド抗生物質複合体およびその使用方法
|
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
|
EP3694860A1
(en)
|
2017-10-10 |
2020-08-19 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazine compounds and methods of inhibiting tam kinases
|
|
WO2019079819A1
(en)
|
2017-10-20 |
2019-04-25 |
City Of Hope |
COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
|
|
BR112020008825A2
(pt)
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
moduladores da via de estresse integrada
|
|
MX2020004537A
(es)
|
2017-11-02 |
2020-10-05 |
Calico Life Sciences Llc |
Moduladores de la vía integrada del estrés.
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
JP2021501785A
(ja)
|
2017-11-02 |
2021-01-21 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
MX2020004538A
(es)
|
2017-11-02 |
2020-09-18 |
Calico Life Sciences Llc |
Moduladores de la vía de estrés integrada.
|
|
EP3704125B1
(en)
|
2017-11-02 |
2026-03-11 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
|
SG11202004009TA
(en)
|
2017-11-02 |
2020-05-28 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
AU2018360766B2
(en)
|
2017-11-06 |
2024-09-19 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
|
US11612604B2
(en)
|
2017-12-06 |
2023-03-28 |
Ludwig Institute For Cancer Research Ltd |
Methods of treating cancer with PLK4 inhibitors
|
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
EP3720438B1
(en)
|
2017-12-07 |
2023-08-30 |
Amplyx Pharmaceuticals, Inc. |
Heterocycle substituted pyridine derivative antifungal agents
|
|
IL275059B2
(en)
|
2017-12-15 |
2023-11-01 |
Pyramid Biosciences Inc |
5-(2-(5,2-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[5,1-A]pyrimidine derivatives and related compounds as TRK kinase inhibitors for cancer therapy
|
|
US11939575B2
(en)
|
2017-12-19 |
2024-03-26 |
City Of Hope |
Modified tracrRNAs gRNAs, and uses thereof
|
|
CA3088529A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
AU2019209470A1
(en)
|
2018-01-16 |
2020-08-13 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
US10683280B2
(en)
|
2018-01-26 |
2020-06-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
JP7325425B2
(ja)
|
2018-02-08 |
2023-08-14 |
ネオンク テクノロジーズ インク． |
血液脳関門を透過性にする方法
|
|
CN112135825A
(zh)
|
2018-03-13 |
2020-12-25 |
夏尔人类遗传性治疗公司 |
血浆激肽释放酶抑制剂及其用途
|
|
MX2020011344A
(es)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences Inc |
Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
|
|
PL3788049T3
(pl)
|
2018-05-01 |
2023-06-19 |
Revolution Medicines, Inc. |
Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
|
|
EP3788050B1
(en)
|
2018-05-01 |
2024-08-28 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mtor inhibitors
|
|
SI3788044T1
(sl)
|
2018-05-03 |
2023-12-29 |
Rigel Pharmaceuticals, Inc. |
Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
|
|
PL3788045T3
(pl)
|
2018-05-03 |
2023-10-09 |
Rigel Pharmaceuticals, Inc. |
Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
|
|
WO2019213611A1
(en)
|
2018-05-04 |
2019-11-07 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
|
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
WO2019236901A1
(en)
|
2018-06-06 |
2019-12-12 |
The Regents Of The University Of California |
Estrogen receptor inhibitors and uses therof
|
|
TWI888352B
(zh)
|
2018-06-21 |
2025-07-01 |
美商嘉來克生命科學有限責任公司 |
蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
|
|
JP2021530445A
(ja)
|
2018-06-25 |
2021-11-11 |
アンプリックス ファーマシューティカルズ，インク． |
複素環およびアミノ基によって置換されたピリジン誘導体
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
WO2020041758A1
(en)
|
2018-08-24 |
2020-02-27 |
City Of Hope |
Masked cytokine conjugates
|
|
EA202190590A1
(ru)
|
2018-08-31 |
2021-07-16 |
Ампликс Фармасьютикалз, Инк. |
Соединения и способы лечения грибковых инфекций
|
|
CN118271374A
(zh)
|
2018-09-10 |
2024-07-02 |
加利福尼亚大学董事会 |
二硫醇糖粘液溶解剂和其用途
|
|
TW202545902A
(zh)
|
2018-10-11 |
2025-12-01 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
AU2019372677B2
(en)
|
2018-11-01 |
2024-05-30 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof
|
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
WO2020118683A1
(en)
|
2018-12-14 |
2020-06-18 |
Lynk Pharmaceuticals Co. Ltd. |
Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
|
|
CA3126224A1
(en)
|
2019-01-08 |
2020-07-16 |
Corxel Pharmaceuticals Hong Kong Limited |
Metalloenzyme inhibitor compounds
|
|
KR102983496B1
(ko)
|
2019-03-14 |
2026-06-29 |
칼리코 라이프 사이언시스 엘엘씨 |
단백질 티로신 포스파타제 억제제 및 이의 사용 방법
|
|
PH12021552759A1
(en)
|
2019-04-30 |
2022-07-04 |
Abbvie Inc |
Substituted cycloalkyls as modulators of the integrated stress pathway
|
|
EP3968979B1
(en)
|
2019-05-15 |
2026-07-01 |
Bexson Biomedical, Inc. |
KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
|
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
WO2020252487A1
(en)
|
2019-06-14 |
2020-12-17 |
Children's Hospital Medical Center |
Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
|
|
EP4009974A1
(en)
|
2019-08-08 |
2022-06-15 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating cytokine release syndrome
|
|
CA3147444A1
(en)
|
2019-08-14 |
2021-02-18 |
Rigel Pharmaceuticals, Inc. |
Method of blocking or ameliorating cytokine release syndrome
|
|
JP2022545542A
(ja)
|
2019-08-30 |
2022-10-27 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
|
|
AU2020341708B2
(en)
|
2019-09-06 |
2024-01-04 |
Rigel Pharmaceuticals, Inc. |
RIP1 inhibitory compounds and methods for making and using the same
|
|
ES3043457T3
(en)
|
2019-09-06 |
2025-11-25 |
Rigel Pharmaceuticals Inc |
Rip1 inhibitory compounds and methods for making and using the same
|
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
|
CN114728962B
(zh)
|
2019-09-18 |
2025-09-19 |
武田药品工业有限公司 |
血浆激肽释放酶抑制剂及其用途
|
|
US20220348632A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Nkg2d fusion proteins and uses thereof
|
|
US12516145B2
(en)
|
2019-09-30 |
2026-01-06 |
Northwestern University |
Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization
|
|
AU2020365951B2
(en)
|
2019-10-14 |
2026-07-16 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
US12441890B2
(en)
|
2019-10-30 |
2025-10-14 |
Northwestern University |
Selenium-containing analogues of pheomelanin and related materials and methods of making
|
|
SMT202600151T1
(it)
|
2019-11-07 |
2026-05-12 |
Rigel Pharmaceuticals Inc |
Composti eterociclici inibitori di rip1
|
|
US12006318B2
(en)
|
2019-11-13 |
2024-06-11 |
Rapt Therapeutics, Inc. |
Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof
|
|
MX2022007441A
(es)
|
2019-12-18 |
2022-09-02 |
Calico Life Sciences Llc |
Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
|
|
KR102993352B1
(ko)
|
2019-12-20 |
2026-07-22 |
프린시피아 바이오파마, 인코퍼레이티드 |
2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
|
|
WO2021150723A1
(en)
|
2020-01-22 |
2021-07-29 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
IL296921B1
(en)
|
2020-04-15 |
2026-08-01 |
Pyramid Biosciences Inc |
Methods for preparing receptor tyrosine kinase inhibitors
|
|
US12678510B2
(en)
|
2020-05-01 |
2026-07-14 |
Northwestern University |
Drug loaded peptide brush polymers
|
|
IL312785B2
(en)
|
2020-05-19 |
2026-06-01 |
Cybin Irl Ltd |
Deuterated tryptamine derivatives and methods of use
|
|
GB202008919D0
(en)
*
|
2020-06-11 |
2020-07-29 |
Univ Birmingham |
Polysaccharide conpositions and therapeutic gels
|
|
JP2023539113A
(ja)
|
2020-08-18 |
2023-09-13 |
サイビン アイアールエル リミテッド |
フェネチルアミン誘導体、組成物およびその使用方法
|
|
CA3194653A1
(en)
|
2020-10-02 |
2022-04-07 |
Mitokinin, Inc. |
Compositions and methods of treating kidney disease and fibrosis
|
|
PE20231656A1
(es)
|
2020-11-02 |
2023-10-17 |
Trethera Corp |
Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
|
|
EP4247340A4
(en)
|
2020-11-18 |
2024-10-02 |
Bexson Biomedical, Inc. |
COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
|
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
WO2022197755A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Imidazopyridinyl inhibitors of plasma kallikrein
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
EP4585265A3
(en)
|
2021-03-17 |
2025-10-15 |
Takeda Pharmaceutical Company Limited |
Heteroaryl inhibitors of plasma kallikrein
|
|
US20240382482A1
(en)
|
2021-03-17 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors
|
|
US20240199613A1
(en)
|
2021-03-17 |
2024-06-20 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|
|
US20240226106A1
(en)
|
2021-03-17 |
2024-07-11 |
Shire Human Genetic Therapies, Inc. |
Inhibitors of plasma kallikrein
|
|
US20240217981A1
(en)
|
2021-04-13 |
2024-07-04 |
Pipeline Therapeutics, Inc. |
Crystalline compound of muscarinic acetylcholine m1 receptor antagonists
|
|
US20250236589A1
(en)
|
2022-02-15 |
2025-07-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
|
AU2023222126A1
(en)
|
2022-02-15 |
2024-08-08 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
ES3075943T3
(en)
|
2022-03-23 |
2026-08-10 |
Rigel Pharmaceuticals Inc |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
WO2023192479A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
|
CA3255429A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine Receptor Modulators and Their Uses
|
|
CN114504550B
(zh)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
一种包含甲硝唑的眼用凝胶及其制备方法
|
|
EP4531859A4
(en)
|
2022-05-25 |
2026-05-27 |
Revolution Medicines Inc |
CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
|
|
US12377036B2
(en)
|
2022-06-21 |
2025-08-05 |
Northwestern University |
Melanin hair dye with thickeners
|
|
US20250034115A1
(en)
|
2023-07-12 |
2025-01-30 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
|
EP4743061A1
(en)
|
2023-07-13 |
2026-05-20 |
Comanche Biopharma Corp. |
Formulations of nucleic acid compounds and uses thereof
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
WO2025068803A1
(en)
|
2023-09-26 |
2025-04-03 |
Astrazeneca Ab |
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
EP4623919A1
(en)
|
2024-03-28 |
2025-10-01 |
Marinomed Biotech AG |
Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions
|
|
WO2026022243A1
(en)
|
2024-07-23 |
2026-01-29 |
The Trustees Of The University Of Pennsylvania |
Combination of a gsk-3 inhibitor and a lsd-1 inhibitor for use in the treatment of cancer
|